For DeepTech funder Cambridge Innovation Capital, it’s a case of back to the future after its decision to take venture ...

Alltrna’s CEO Michelle Warner said that the approach allows for basket trials that can group patients with different diseases ...

Trimtech Therapeutics has closed a seed funding round of $31m (£25m) to advance its pipeline of CNS penetrant therapeutics.

Synthetic biology specialist GRO Biosciences started exploring strategic alternatives about six months after raising a series ...

X-linked severe combined immunodeficiency disease (X-SCID) is a rare genetic disorder characterized by profound defects in ...

Mary Berry’s simple recipe calls for just three ingredients ― egg, milk, and flour, along with a little oil.

TRIMTECH Therapeutics raises $31M to enhance its TRIMTAC platform, targeting protein aggregates in neurodegenerative diseases for improved therapeutic outcomes.

TRIMTECH Therapeutics’s incredible $31million seed funding haul will be deployed to develop treatments for severe ...

Biopharma companies require optimal clone yields to ensure maximum concentration and effectiveness of these therapeutic ...

The team was able to reach protein yields at the pool stage that couldn’t be achieved previously with a random integration approach.

KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...

Peptides designed by artificial intelligence restrict both drug-resistant bacteria and rapidly evolving viruses.